Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Merck
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,168,326

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,168,326
Title:Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 .mu.g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
Inventor(s): Stubenrauch; Kay-Gunnar (Penzberg, DE), Vogel; Rudolf (Weilheim, DE)
Assignee: F. HOFFMANN-LA ROCHE INC. (Nutley, NJ)
Application Number:15/078,140
Patent Claims:1. An interference-suppressed immunoassay for the detection of anti-drug antibodies against a drug antibody for the treatment of rheumatoid arthritis, juvenile arthritis, or osteoarthritis, said method comprising: (a) incubating a sample from a rheumatoid arthritis, juvenile arthritis, or osteoarthritis patient treated with said drug antibody simultaneously with a mixture comprising 0.5 .mu.g/ml to 10 .mu.g/ml of a 1:1 conjugate of said drug antibody to a first member of a binding pair via a single lysine residue as a capture drug antibody and 0.5 .mu.g/ml to 10 .mu.g/ml of a 1:1 conjugate of said drug antibody to a detectable label via a single lysine residue as a tracer drug antibody for 0.5 to 24 hours to generate a capture drug antibody/anti-drug antibody/tracer drug antibody complex, wherein the sample comprises 1% to 20% serum and is supplemented with oligomeric human IgG prior to the incubation to a final concentration of 10 .mu.g/ml to 1000 .mu.g/ml, (b) immobilizing the capture drug antibody/anti-drug antibody/tracer drug antibody complex formed in step (a) on a solid phase by covalently or non-covalently conjugating said first member of a binding pair to a second member of a binding pair on the solid phase, (c) incubating the immobilized complex with an antibody against the detectable label of the tracer drug antibody, conjugated to a second detectable label, and (d) detecting the anti-drug antibodies against said drug antibody via a signal of the detectable label of the antibody of step (c), and wherein the drug antibody is an anti-inflammatory antibody.

2. The method of claim 1, wherein the patient is a rheumatoid arthritis patient.

3. The method of claim 1, wherein the first member of a binding pair in said capture antibody is biotin, and the detectable label in said tracer antibody is digoxygenin.

4. The method of claim 3, wherein in step (b) the second member of a binding pair is streptavidin.

5. The method of claim 1 or 2, wherein the sample comprises anti-drug antibodies and rheumatoid factors.

6. The method of any one of claims 1 to 4, wherein the drug antibody is an anti-IL6R antibody.

7. The method of claim 6, wherein the anti-IL6R antibody is tocilizumab.

Details for Patent 10,168,326

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. ACTEMRA tocilizumab Injection 125276 2010-01-08 ⤷  Try it Free 2033-07-04
Genentech, Inc. ACTEMRA tocilizumab Injection 125472 2013-10-21 ⤷  Try it Free 2033-07-04
Genentech, Inc. ACTEMRA tocilizumab Injection 125472 2018-11-19 ⤷  Try it Free 2033-07-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKesson
Colorcon
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.